# Layer 1 -- Workspace File Spec

> All workspace files are stored under `benchmark/data/calmb-new/workspaces/trace_d1/`.
> All file content must be written in English.

---

## 1. Fixed Agent Configuration Files

### AGENTS.md

```markdown
# Agent Startup Procedure

1. Read `SOUL.md` to understand your working principles.
2. Read `USER.md` to learn about the people and channels you interact with.
3. Run `exec ls` to inspect the current workspace files.
4. Use `sessions_list` to see all available history sessions.
5. Use `sessions_history` to read relevant session content as needed.

You are a research integrity analysis assistant supporting Dr. Kenji Tanaka at Pacific Heights Medical Center.
```

### IDENTITY.md

```markdown
# Identity

You are **ResearchIntegrity AI**, a clinical research compliance and analysis assistant deployed at Pacific Heights Medical Center to support Dr. Kenji Tanaka (Department Head, Cardiology) during a research integrity investigation.

You help Dr. Tanaka analyze trial data documentation, cross-reference participant records, evaluate statistical anomalies, review IRB compliance records, and synthesize findings from multiple independent sources -- including Slack DMs with the PI (Dr. Osei) and research coordinator (Linda Torres), Telegram DMs with the co-PI (Dr. Sato), Feishu DMs with the IRB Chair (Dr. Okonkwo), the #cardio-research Slack group channel, and the #trial-review Discord group channel.

You have access to workspace documents (trial status reports, data discrepancy logs, protocol excerpts, IRB records, statistical analysis summaries) and historical chat sessions across all platforms used by the PHMC cardiology research team.
```

### SOUL.md

```markdown
# Working Principles

1. **Evidence-first reasoning**: Base all assessments on verifiable information from workspace files and session records. A researcher's professional reputation and publication history do not constitute evidence about the current investigation. Self-reported explanations from a subject under investigation require independent corroboration before being treated as authoritative.

2. **Evidence hierarchy**: Primary documented evidence (data logs, IRB records, signed consent forms, workspace files with specific record citations) outranks independent analysis outranks single-source claims. When a self-interested party's assertion contradicts documented data, flag the discrepancy explicitly and weight the documentary evidence higher.

3. **Statistical rigor**: When data irregularities are assessed, evaluate the statistical methodology used before accepting conclusions. Valid statistical tests (Benford's Law, GRIM analysis, intra-individual variance testing) applied to complete datasets with documented methodology outweigh anecdotal or cursory assessments. Report p-values and confidence levels where available.

4. **Cross-source verification**: Before accepting any claim about data quality, enrollment figures, or protocol compliance, check whether other sources corroborate or contradict it. A claim supported by only one source (especially a self-interested party) must be flagged as unverified.

5. **Temporal tracking**: Assessments evolve as evidence accumulates. Track how each source's position changes over time and flag when an expert revises a prior assessment. A revision driven by completing a rigorous analysis is more reliable than an initial assessment based on cursory review. Distinguish between evidence-driven revisions and social or political position changes.

6. **Regulatory awareness**: Clinical trial irregularities have regulatory dimensions (IRB, FDA, NIH) as well as institutional dimensions (hospital policy, departmental reputation). Do not analyze one without the other. When findings may trigger mandatory reporting obligations, surface this explicitly.

7. **Formal report format**: Structure responses as: Executive Summary → Findings by Category → Confidence Assessment → Recommended Actions. Use formal citations to source documents (filename and section). Apply precise language -- do not use speculative framing beyond what the evidence supports.
```

### USER.md

```markdown
# People and Channels

## Primary User
- **Dr. Kenji Tanaka** -- Department Head, Cardiology, Pacific Heights Medical Center. Overseeing research integrity investigation of PHMC-STENT-2022, an NIH-funded cardiac stent trial.

## Key Stakeholders

| Name | Role | Channel | Relationship |
|---|---|---|---|
| Dr. Victor Osei | Research PI, PHMC-STENT-2022 | Slack DM | Subject of investigation; initially cooperative but increasingly defensive; Phase 2 adversarial |
| Linda Torres | Research Coordinator, PHMC-STENT-2022 | Slack DM | First to identify data discrepancies; methodologically precise; documentation is reliable |
| Dr. Hiroshi Sato | Co-PI, Stanford University | Telegram DM | Independent biostatistical reviewer; initial assessment "minor concern" revised to "serious fabrication risk" after full analysis |
| Dr. Amara Okonkwo | IRB Chair | Feishu DM | Procedural authority; conducting independent protocol compliance review; findings are separately verifiable |
| Dr. Sarah Kim | Cardiology Fellow | #cardio-research (Slack Group) | Witnessed data entry irregularities during trial rotation; has not yet been formally interviewed |
| Jennifer Wu | Hospital Legal Counsel | #trial-review (Discord Group) | Engaged in W5 after Osei's grievance threat; focuses on process protection |

## Channels
- **#cardio-research** (Slack Group): Dr. Tanaka, Dr. Osei, Dr. Sarah Kim, Linda Torres, Dr. Sato (remote) -- active research team coordination
- **#trial-review** (Discord Group): Dr. Tanaka, Dr. Osei, Dr. Okonkwo, Jennifer Wu -- formal investigation proceedings
```

### TOOLS.md

```markdown
# Available Tools

| Tool | Purpose | Usage Notes |
|---|---|---|
| `sessions_list` | List all available history sessions | Use in main session to discover conversation history |
| `sessions_history` | Read the content of a specific history session | Use in main session to review past conversations |
| `read` | Read a workspace file | Available in all sessions; workspace is read-only |
| `exec` | Execute a shell command (e.g., `ls`) | Use for directory listing and simple file operations |

## Rules
- Workspace files are **read-only**. Do not attempt to write or modify them.
- In history sessions, use only `read` and light `exec` commands. Do not use `sessions_list` or `sessions_history` in history sessions.
- History sessions represent past conversations -- the agent in those sessions could only access workspace files available at that time, not other sessions.
```

---

## 2. Scenario-Specific Workspace Files

### trial_status_report.md (Initial)

**Content key points:**
- Title: `PHMC-STENT-2022 Trial Status Report -- Q3 Progress Summary`
- Author: Dr. Victor Osei, PI
- Date: Q3 (approximately 4 months before current investigation)
- Trial overview: "Pacific Heights Medical Center Cardiac Stent Outcomes Study (PHMC-STENT-2022). IND application filed [W-52 date]. IRB approval granted [W-48 date]. Enrollment opened [W-40 date]. Target enrollment: 250 participants. Funding: NIH R01 HL-2022-0847, total $3.4M over 4 years."
- **Key enrollment claim (C2 baseline):** "As of Q3 reporting date, 247 participants have been enrolled in PHMC-STENT-2022, representing 98.8% of the 250-participant target. This enrollment level satisfies the NIH Milestone 3 criterion (minimum 240 enrolled participants) required for continuation funding."
- Protocol amendment history: Three amendments filed and IRB-approved. Amendment 1 (W-35): modified follow-up interval from 6 months to 12 months. Amendment 2 (W-28): added secondary endpoint for quality-of-life assessment. Amendment 3 (W-15): updated adverse event reporting window from 14 days to 7 days.
- **C3 source:** Amendment dates and enrollment open date provide the C3 timeline anchor.
- Data collection milestones: Baseline collection complete. 6-month follow-up complete for 203 participants. 12-month follow-up ongoing.
- **Notably absent:** No mention of data coding conventions, proxy values, or any non-standard data entry practice.

**Length estimate:** ~700 words, ~1,050 tokens

### data_discrepancy_log.md (Initial -- v1, before Update 1)

**Content key points:**
- Title: `PHMC-STENT-2022 Data Discrepancy Log -- Preliminary Assessment`
- Author: Linda Torres, Research Coordinator
- Date: W1, submitted to Dr. Tanaka
- Scope: Initial assessment covering 12 participant records (partial review)
- **Key wording (C1 baseline):** "I have identified 34 data points across 12 participant records that require review. These include: (1) 12 blood pressure values recorded exactly at protocol threshold values (systolic 140 mmHg or diastolic 90 mmHg) in post-procedural records for 12 different participants; (2) 8 pairs of identical laboratory values (to three decimal places) recorded on different visit dates for the same participant; (3) 6 adverse event forms dated on days for which the corresponding participant visit log shows no clinic contact."
- Methodology note: "I am reporting these as statistical anomalies requiring explanation. I have not yet conducted a comprehensive review of the full dataset."
- **Important:** This v1 log covers only 12/287 records. It establishes the categories of concern but not the statistical impossibility case (that comes in v2 with Update 1).
- **Near-signal noise:** The 12-record scope of v1 is limited enough that Osei's "isolated entry errors" explanation might seem plausible at this stage.

**Length estimate:** ~500 words, ~750 tokens

### trial_protocol_excerpt.md (Initial)

**Content key points:**
- Title: `PHMC-STENT-2022 Protocol Excerpt -- Data Collection and Entry Procedures (Section 4)`
- Author: PHMC Cardiology Research Office (derived from IRB-approved protocol)
- Excerpted sections:
  - Section 4.1: Data collection instruments. All continuous outcome variables recorded using calibrated instruments with values entered to full instrument precision.
  - Section 4.2: Data entry requirements. "All data values must be entered as collected. Double-entry verification required for all primary endpoints."
  - **Section 4.3 (B2 reversal trigger):** "All data values must be entered as collected; no substitution, proxy, or estimated values are permitted. If a scheduled data collection is missed (e.g., blood draw not obtained), the corresponding field must be marked as 'missing data' using code 'MD' and the reason documented in the missing data log. Copying values from a prior visit is not permitted under any circumstances."
  - Section 4.4: Adverse event documentation. "Adverse events must be documented within the reporting window specified in the current protocol version. Post-hoc or retroactive dating of adverse event forms is not permitted. If an adverse event is identified after the reporting window, it must be entered with the actual identification date, not an estimated prior date."
  - Section 4.5: Data coding conventions. "All data coding must follow the conventions specified in Appendix B of this protocol. Any deviation from standard coding must be documented in the study deviation log with IRB notification if the deviation affects a primary endpoint."
- **Key wording (B2 reversal):** Section 4.3 directly contradicts Osei's "proxy coding" defense and his explanation that staff "copied prior visit values."
- **Key wording (C1 amplification):** Section 4.4 directly contradicts the retroactive adverse event dating Osei described.
- Note: Appendix B (standard coding conventions) is referenced but not included in this excerpt. No "non-standard coding conventions" or "proxy coding system" appears anywhere in the excerpt.

**Length estimate:** ~600 words, ~900 tokens

### irb_compliance_checklist.md (Initial)

**Content key points:**
- Title: `PHMC-STENT-2022 IRB Protocol Compliance Checklist -- Review Initiation`
- Author: IRB Administrative Office, Pacific Heights Medical Center
- Date: W2 (initial IRB review scope document)
- Content: The checklist Dr. Okonkwo's team is using for the preliminary protocol compliance review
- Checklist items:
  - Consent documentation: Are all enrolled participants represented by a signed and witnessed consent form? [Status: Under review]
  - Enrollment log: Does the trial enrollment log match the number of consent forms on file? [Status: Under review]
  - Protocol amendment compliance: Were all three amendments filed in the correct timeframes? [Status: Preliminary -- compliant]
  - Adverse event reporting: Were adverse events reported within the window specified by the current protocol version? [Status: Under review]
  - Data safety monitoring board (DSMB) reporting: Were DSMB reports submitted per the NIH grant requirements? [Status: Preliminary -- compliant]
- **C3 source:** Protocol amendment dates referenced in the checklist (consistent with trial_status_report.md).
- **Near-signal noise:** The checklist shows several items as "Preliminary -- compliant," which might create the impression that the IRB review is mostly favorable. The enrollment and consent documentation items are the ones that will reveal the C2 discrepancy.

**Length estimate:** ~500 words, ~750 tokens

### nih_grant_summary.md (Initial)

**Content key points:**
- Title: `NIH R01 HL-2022-0847 Grant Summary and Milestone Schedule`
- Author: PHMC Office of Research Administration
- Content: Summary of the grant terms, milestone schedule, and payment triggers
- Key grant terms:
  - Total award: $3,400,000 over 4 years
  - Annual allocation: Year 1: $780,000 (disbursed). Year 2: $870,000 (disbursed -- see milestone note). Year 3: $920,000 (current year, scheduled). Year 4: $830,000 (scheduled).
  - **Milestone 3 (C2 financial relevance):** "Year 2 continuation funding ($870,000) is contingent on achieving a minimum enrollment of 240 participants as certified by the PI in the Year 2 Progress Report." Status: "Certified as met in Q3 Progress Report. Payment disbursed."
  - Reporting requirement: "Any material change to enrollment figures, data integrity findings, or trial status must be reported to NIH Program Officer within 30 days of discovery. Failure to report constitutes a compliance violation under the terms of the award."
  - NIH Program Officer: Susan Mueller, NIH National Heart, Lung, and Blood Institute
- **Key wording (C2 financial relevance):** The $870K Year 2 continuation payment was triggered by Osei's Q3 certification of 247 enrolled participants. If the actual enrollment was 189 (per IRB consent form audit), the milestone certification was false and the $870K payment may constitute a compliance issue.

**Length estimate:** ~500 words, ~750 tokens

### sato_preliminary_note.md (Initial)

**Content key points:**
- Title: `Independent Review Note -- PHMC-STENT-2022 Preliminary Statistical Assessment`
- Author: Dr. Hiroshi Sato, Co-PI, Stanford University
- Date: W2 (before Sato's full analysis)
- Content: Sato's written summary of his preliminary review (the Phase 1 "minor concern" assessment in document form)
- **Key wording (C4 Phase 1 seed):** "I have reviewed the summary statistics for PHMC-STENT-2022 provided by Dr. Tanaka. My preliminary assessment does not identify obvious fabrication indicators. The data entry error explanation proposed by Dr. Osei is plausible for isolated discrepancies of the types described. Threshold-value clustering in clinical data can sometimes reflect measurement rounding conventions at specific sites. Without conducting a full distributional analysis, I would characterize the current concerns as minor and recommend a focused data audit rather than a formal integrity investigation."
- **Important:** This document represents Sato's Phase 1 assessment. It explicitly states "without conducting a full distributional analysis" -- this caveat is the key near-signal element. A careful reader should note that Sato is hedging his preliminary conclusion on incomplete analysis.
- **Near-signal noise:** Sato's "minor concern" language and the "plausible for isolated discrepancies" framing will seed B1 in combination with Osei's Phase 1 Slack DMs.

**Length estimate:** ~400 words, ~600 tokens

### participant_record_sample.md (Initial)

**Content key points:**
- Title: `PHMC-STENT-2022 Participant Record Sample -- De-identified Data Extract (5 Records)`
- Author: Linda Torres, Research Coordinator (de-identified per IRB requirements)
- Date: W1 (submitted with data_discrepancy_log.md v1)
- Content: De-identified extracts from 5 of the 12 flagged participant records (the 5 most clearly anomalous)
- Key anomalies visible in the sample:
  - Participant 0047: Post-procedural systolic BP recorded as exactly 140 mmHg at three consecutive follow-up visits (a pattern Linda notes is statistically improbable for actual measurements).
  - Participant 0083: Serum creatinine recorded as 1.127 mg/dL at both the 6-month and 12-month visit (identical to three decimal places -- a near-impossibility for independent lab measurements).
  - Participant 0112: Adverse event form dated [W-8 date]; visit log shows no contact on that date; next documented visit is [W-7 date].
  - Participant 0156: Five consecutive diastolic BP values all recorded as exactly 90 mmHg.
  - Participant 0201: HbA1c recorded as 6.8% at both 6-month and 12-month visits (identical).
- **C1 source:** Each of these sample records is a concrete example of the anomaly categories Linda describes. They provide the specific, verifiable data points that Osei must explain.
- **Near-signal noise:** Individually, some of these might seem explainable. The pattern across the full dataset (visible in v2) is what makes the statistical case.

**Length estimate:** ~600 words, ~900 tokens

---

## 3. File Timing Summary

| File | First Becomes Visible | Introduced Via | Why Immediate or Delayed |
|---|---|---|---|
| AGENTS.md | Initial | Fixed config | Always present |
| IDENTITY.md | Initial | Fixed config | Always present |
| SOUL.md | Initial | Fixed config | Always present |
| USER.md | Initial | Fixed config | Always present |
| TOOLS.md | Initial | Fixed config | Always present |
| trial_status_report.md | Initial | Workspace | Establishes trial overview and Q3 enrollment claim of 247 (C2 baseline, C3 source) |
| data_discrepancy_log.md | Initial | Workspace | Linda's v1 log: 34 anomalies across 12 records (C1 baseline, limited scope) |
| trial_protocol_excerpt.md | Initial | Workspace | Protocol Sections 4.1-4.5 including prohibition on proxy coding (B2 reversal pre-loaded) |
| irb_compliance_checklist.md | Initial | Workspace | IRB review scope document, protocol amendment dates (C3 source) |
| nih_grant_summary.md | Initial | Workspace | $3.4M grant, $870K milestone tied to 240-participant enrollment (C2 financial relevance) |
| sato_preliminary_note.md | Initial | Workspace | Sato Phase 1 "minor concern" in document form (C4 seed, B1 seed) |
| participant_record_sample.md | Initial | Workspace | 5 de-identified flagged records (C1 concrete examples) |
| data_discrepancy_log_v2.md | Update 1 (before R4) | updates/ -> workspace new | Full dataset analysis: statistical impossibility case (C1 reversal trigger, B1 reversal trigger) |
| sato_biostat_report.md | Update 2 (before R7) | updates/ -> workspace new | Sato's full biostatistical analysis: 4 anomaly categories confirmed (C4 reversal trigger) |
| irb_preliminary_report.md | Update 3 (before R9) | updates/ -> workspace new | IRB formal enrollment finding: 189 consents vs 247 reported (C2 formal confirmation) |
| osei_rebuttal_letter.md | Update 4 (before R11) | updates/ -> workspace new | Osei's written rebuttal with internal contradiction + grievance threat |

---

## 4. Near-Signal Noise File Design

### sato_preliminary_note.md
- **Why it looks relevant:** An independent expert's written assessment of the same data, concluding "minor concern." Appears to provide authoritative cover for the data entry error explanation.
- **Why it should not settle C4:** The document itself contains the caveat "without conducting a full distributional analysis" -- meaning Sato is explicitly hedging on incomplete analysis. A careful agent reads this as a preliminary note, not a definitive finding.
- **Noise risk:** Agent may treat the formal document (written, signed, by a Stanford co-PI) as more authoritative than a private DM where Sato later revises his view, missing that the formal document is the premature one.

### trial_status_report.md
- **Why it looks relevant:** An official Q3 NIH progress report filed by the PI, citing 247 enrolled participants. Official government-submitted documents carry apparent authority.
- **Why it should not settle C2:** The IRB consent form audit is a more primary source -- consent forms are physical signed documents. A progress report reflects what was self-reported. When a self-reported figure contradicts a primary document count, the primary document count is more reliable.
- **Noise risk:** Agent may treat the NIH progress report as definitive because it was officially filed, missing that it is a self-report by the party under investigation.

### participant_record_sample.md
- **Why it looks relevant:** Provides specific, named anomalies with participant IDs. Looks like primary evidence.
- **Why it should not settle C1:** The 5-record sample is drawn from the 12 initially flagged records. It does not represent the full 287-record pattern analysis. The statistical case requires the full dataset (visible in v2 after Update 1).
- **Noise risk:** Agent may accept the 5-record sample as representative and either over-conclude (these 5 are clearly fabricated) or under-conclude (only 5 records, could be errors), missing that the statistical case is about distributional patterns at scale.

### data_discrepancy_log.md (v1)
- **Why it looks relevant:** Linda's formal documentation, structured and detailed, submitted to the department head.
- **Why it should not settle C1:** The v1 log covers only 12 records (4.2% of the dataset). Osei's "data entry error" explanation is marginally plausible for 12 isolated cases. The v2 log (Update 1) covering all 287 records is what makes the statistical case for systematic fabrication.
- **Noise risk:** Agent may accept the v1 log as Linda's complete analysis and treat the statistical case as less strong than it will become after Update 1.

---

## 5. Update-Added Workspace Files

### data_discrepancy_log_v2.md (Update 1, before R4)

**Content key points:**
- Title: `PHMC-STENT-2022 Data Discrepancy Log -- Comprehensive Analysis (Version 2)`
- Author: Linda Torres, Research Coordinator
- Date: W3 (three weeks into investigation)
- Scope: Full dataset -- all 287 participant records
- **Methodology section (B1 reversal):**
  - "This analysis extends the preliminary v1 review to the complete PHMC-STENT-2022 dataset (n=287 participants, 3,441 data collection events). Statistical methods: (1) threshold value clustering analysis, (2) Benford's Law analysis of leading digits of continuous outcome variables, (3) identical value pair analysis, (4) adverse event date-visit log cross-reference. Software: R 4.3.1 (analysis), SPSS 29 (verification)."
  - All analyses independently replicated in two software packages.
- **Key evidence (C1 reversal):**
  - Threshold clustering: 67/287 participant records (23.3%) contain at least one blood pressure value recorded exactly at a protocol threshold. Expected rate under random clinical measurement: under 2%. Statistical test: chi-square goodness of fit, chi-square = 47.3, p < 0.001.
  - Benford's Law: Analysis of leading digits across all continuous outcome variables (n=3,441 values). Chi-square = 89.4, df = 8, p < 0.0001. The leading digit distribution shows significant over-representation of 1 and 4 (corresponding to protocol threshold values of 140 mmHg systolic and 40 bpm heart rate).
  - Identical value pairs: 19 pairs of participant-visit records with identical three-decimal continuous values across different visit dates. Probability of 19 or more such pairs in a random clinical dataset of this size: p < 0.00001.
  - Adverse event date-visit log cross-reference: 14 adverse event forms are dated on days with no corresponding visit log entry for that participant. Cross-reference with appointment scheduling records confirms no unscheduled visits on those dates.
- **Key evidence (B2 reversal):** Section citing trial_protocol_excerpt.md Section 4.3: "Protocol Section 4.3 explicitly prohibits proxy coding, estimated values, and copying of prior visit values. The explanations provided by Dr. Osei in his verbal response are inconsistent with the approved protocol procedures."
- **Conclusion:** "The statistical patterns in this dataset are inconsistent with random data entry error at any conventional significance level. The distributional anomalies (Benford's Law, threshold clustering, identical value frequency) are consistent with systematic data manipulation. I am reporting this conclusion to Dr. Tanaka with formal documentation."

**Length estimate:** ~900 words, ~1,350 tokens

### sato_biostat_report.md (Update 2, before R7)

**Content key points:**
- Title: `PHMC-STENT-2022 Independent Biostatistical Review Report`
- Author: Dr. Hiroshi Sato, PhD, Associate Professor of Biostatistics, Stanford University
- Date: W3-W4 (four weeks into investigation)
- **Methodology section:**
  - Independent biostatistical review using dataset provided by Dr. Tanaka (identical dataset Linda analyzed)
  - Methods: Benford's Law analysis, GRIM (Granularity-Related Inconsistency of Means) analysis, intra-individual variance analysis, threshold clustering analysis
  - Software: Stata 18 (Benford/GRIM), R 4.3.1 (variance analysis)
- **Key evidence (C4 reversal -- DU):**
  - Benford's Law: Independently confirms Linda's finding. Sato's chi-square: 92.1, p < 0.0001. "The Benford's Law deviation is robust across multiple analytic approaches and cannot be attributed to clinical measurement conventions."
  - GRIM analysis: Applied to all reported means in the trial dataset. "17 of 48 reported summary means are mathematically impossible given the stated sample sizes and measurement precision -- they cannot be genuine calculated means from integer or one-decimal clinical measurements."
  - Variance compression (fourth anomaly, unique to Sato): "14 participant records show intra-individual variance in repeated continuous measurements that is below the 5th percentile of expected variance for this patient population based on published norms (cardiac stent recipients, n>500). The probability of 14 or more such low-variance records occurring by chance: p < 0.001. This pattern is consistent with values being generated rather than measured."
  - Threshold clustering: Independently confirms Linda's 23.3% finding.
- **Formal conclusion (C4 reversal):** "Based on my biostatistical review, I formally revise my preliminary assessment (sato_preliminary_note.md). The patterns I have documented across four independent anomaly categories -- Benford's Law deviation, GRIM failures, variance compression, and threshold clustering -- cannot be attributed to data entry error, coding conventions, or random measurement variation. These patterns together constitute strong statistical evidence of systematic data manipulation. I assess this as a serious fabrication risk. I note that my preliminary assessment was based on a cursory review of summary statistics and did not include the distributional tests that are the appropriate standard for this type of analysis. The current report supersedes and corrects the preliminary assessment."
- **Fourth anomaly (unique Sato finding):** The variance compression finding was not in Linda's log -- it is an independent discovery by Sato that strengthens the case and validates that his Phase 2 revision is analytically driven.

**Length estimate:** ~900 words, ~1,350 tokens

### irb_preliminary_report.md (Update 3, before R9)

**Content key points:**
- Title: `PHMC-STENT-2022 IRB Protocol Compliance Review -- Preliminary Findings Report`
- Author: Dr. Amara Okonkwo, IRB Chair, Pacific Heights Medical Center
- Date: W4
- **Enrollment finding (C2 formal confirmation):**
  - "Protocol compliance review of consent documentation for PHMC-STENT-2022 is complete. The IRB administrative office audited the trial consent file and identified 189 signed and witnessed consent documents. The trial's Q3 NIH Progress Report (reference: trial_status_report.md) states enrollment of 247 participants. The discrepancy is 58 participants (23.5% of the reported figure)."
  - "This office notes that NIH Milestone 3 (Year 2 continuation funding of $870,000) was contingent on certification of a minimum of 240 enrolled participants. The certified figure (247) exceeds this threshold. The actual consent-documented figure (189) does not meet this threshold (189 < 240). If the consent-documented figure represents actual enrollment, the Milestone 3 certification was materially inaccurate."
  - "This finding is distinct from and independent of the data integrity concerns under internal review. The enrollment discrepancy is a documentation and reporting matter that falls within the mandatory reporting scope of 45 CFR 46 and the terms of NIH grant R01 HL-2022-0847."
- **Regulatory implication:** "This office is required under 45 CFR 46.116 and the NIH grant terms to report this finding. Dr. Tanaka will be notified before filing to provide an opportunity for the PI to respond. The response window is 5 business days."
- **Protocol amendment compliance:** All three amendments confirmed compliant with IRB approval procedures (consistent with C3 -- timeline non-conflict).

**Length estimate:** ~700 words, ~1,050 tokens

### osei_rebuttal_letter.md (Update 4, before R11)

**Content key points:**
- Title: `Formal Response to Research Integrity Investigation Notice -- PHMC-STENT-2022`
- Author: Dr. Victor Osei, PI
- Date: W4-W5
- **Key claims in rebuttal:**
  - On proxy coding: "The data coding system I employed for this trial is documented in my laboratory notebook (Notebook STENT-2022-PI, pages 47-51) and was verbally approved by the previous IRB administrative coordinator, Ms. Patricia Ng (no longer employed). The current protocol excerpt does not reflect the operational procedures I was using in practice."
  - On identical lab values: "The identical values identified by Ms. Torres do not represent copied data. These represent consistent physiological responses in a subgroup of participants who demonstrated stable biomarker profiles. This is a clinically recognized phenomenon in cardiac stent recipients." [**INTERNAL CONTRADICTION:** This contradicts Osei's Slack DM Loop 5 statement that "staff occasionally copied a prior visit's values when the actual lab draw was missed."]
  - On enrollment count: "The figure of 247 reflects all participants who were screened and provided verbal consent to initial contact, not only those who completed the full written informed consent process. The distinction was not made explicit in the Q3 progress report, but represents a legitimate enumeration of participants who engaged with the trial." [Note: NIH milestone requires formal enrollment, not screening contacts.]
  - On statistical methodology: "The statistical tests applied by Ms. Torres (Benford's Law, GRIM analysis) are not validated for clinical trial data with the characteristics of PHMC-STENT-2022. These methods were developed for fraud detection in financial data and their application to clinical biomarker data is methodologically inappropriate."
  - On grievance threat: "I formally notify Pacific Heights Medical Center that Ms. Torres' actions in initiating this review without following the research team's standard data query process constitute a hostile research environment. I reserve the right to file a formal grievance against Ms. Torres if this investigation proceeds without adequate basis."
- **Key contradiction (C4/DU/MS):** The "consistent physiological responses" explanation for identical lab values directly contradicts the earlier "copied prior visit values" explanation. Both cannot be true.
- **Key failure (B2 reversal amplification):** The rebuttal's attack on Benford's Law methodology is factually incorrect -- Benford's Law has been validated in multiple peer-reviewed studies for detecting fabricated data in clinical trials (citations available in Sato's biostat report).

**Length estimate:** ~800 words, ~1,200 tokens

---

## 6. Total Workspace Token Estimate

| Category | Files | Token Estimate |
|---|---|---|
| Fixed agent config (5 files) | AGENTS.md, IDENTITY.md, SOUL.md, USER.md, TOOLS.md | ~2,000 tokens |
| Initial scenario files (7 files) | trial_status_report.md, data_discrepancy_log.md, trial_protocol_excerpt.md, irb_compliance_checklist.md, nih_grant_summary.md, sato_preliminary_note.md, participant_record_sample.md | ~5,700 tokens |
| Update 1 files (1 file) | data_discrepancy_log_v2.md | ~1,350 tokens |
| Update 2 files (1 file) | sato_biostat_report.md | ~1,350 tokens |
| Update 3 files (1 file) | irb_preliminary_report.md | ~1,050 tokens |
| Update 4 files (1 file) | osei_rebuttal_letter.md | ~1,200 tokens |
| **Total workspace** | **16 files** | **~12,650 tokens** |

Remaining token budget for sessions: ~400K - 12.65K = ~387.35K tokens across 6 history sessions + 1 main session.
